18
Oct
Oct
Astellas Pharma Ltd. in the present day introduced that the Medicines and Healthcare merchandise Regulatory Company (MHRA) has authorized PADCEV™ (Enfortumab vedotin, an antibody-drug conjugate [ADC]) together with KEYTRUDA® (pembrolizumab, a PD-1 inhibitor) for the first-line remedy of grownup sufferers with unresectable or metastatic urothelial most cancers who’re candidates for platinum-based chemotherapy. The indication is […]